Sirna targeting mmp7, sirna conjugate and medical use thereof

HK40137352APending Publication Date: 2026-09-11TUOJIE BIOTECH (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124457
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-01-18
Filing Date
2026-06-08
Publication Date
2026-09-11

Smart Images

  • Figure 00000007_0000
    Figure 00000007_0000
Patent Text Reader

Abstract

Relates to siRNA targeting MMP7, siRNA conjugates and medical application thereof. The invention also relates to a pharmaceutical composition, a cell or a kit containing the siRNA, and a method for treating and / or preventing a subject suffering from a related disorder by using the siRNA and the siRNA conjugate.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480032043.X (22) Application Date 2024.06.12 (66) Domestic Priority Data 202310696482.8 2023.06.13 CN 202410074824.7 2024.01.18 CN (85) PCT International Application Entering National Phase Date 2025.11.12 (86) PCT International Application Application Data PCT / CN2024 / 098635 2024.06.12 (87) PCT International Application Publication Data WO2024 / 255759 ZH 2024.12.19 (71) Applicant Shanghai Tuojie Biomedical Technology Co., Ltd. Address 201203 Room 103, Building 14, No. 3728 Jinke Road, Shanghai Pudong New Area Free Trade Zone (72) Inventors: Liu Min, Li Yunfei, Lin Xiaoyan, Wang Yanhui (74) Patent Agency: Beijing Gecheng Intellectual Property Agency Co., Ltd. 11314 Patent Attorney: Cheng Wei (51) Int.Cl. C12N 15 / 113 (2006.01) A61K 31 / 713 (2006.01) A61K 31 / 712 (2006.01) A61K 31 / 7125 (2006.01) A61K 38 / 00 (2006.01) A61P 11 / 00 (2006.01) A61P 35 / 00 (2006.01) (54) Invention Title: siRNA targeting MMP7, siRNA conjugates, and pharmaceutical uses thereof (57) Abstract: This invention relates to siRNA targeting MMP7, siRNA conjugates, and pharmaceutical uses thereof. It also relates to pharmaceutical compositions, cells, or kits containing the siRNA, and methods for using the siRNA or siRNA conjugates to treat and / or prevent related disorders in subjects. CN 121175421 A 2025.12.19 CN 1 21 17 54 21 A